William Blair Begins Coverage on Altimmune (NASDAQ:ALT)

William Blair assumed coverage on shares of Altimmune (NASDAQ:ALT) in a report issued on Friday morning, Marketbeat reports. The brokerage issued a market perform rating on the stock.

Other equities research analysts have also recently issued research reports about the company. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Wednesday, February 5th. Finally, Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Altimmune presently has an average rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Stock Performance

NASDAQ:ALT opened at $6.65 on Friday. Altimmune has a one year low of $5.28 and a one year high of $14.05. The stock has a market cap of $472.98 million, a PE ratio of -4.29 and a beta of 0.19. The stock has a 50 day moving average price of $6.85 and a 200 day moving average price of $7.19.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. As a group, analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ALT. Larson Financial Group LLC purchased a new position in Altimmune in the third quarter valued at $31,000. SBI Securities Co. Ltd. purchased a new stake in Altimmune during the 4th quarter worth about $45,000. Virtus ETF Advisers LLC purchased a new stake in Altimmune during the 4th quarter worth about $60,000. Cullen Frost Bankers Inc. purchased a new stake in Altimmune during the 4th quarter worth about $72,000. Finally, 180 Wealth Advisors LLC purchased a new stake in Altimmune during the 4th quarter worth about $78,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.